Scholarlink

<p>Apoptosis and tumor suppression prevent cell proliferation in response to genomic damage. Polymorphisms in genes involved in these pathways can alter their function, facilitating the onset of cancer. Detecting these polymorphisms would assess the individual risk of developing different types of cancer. Therefore, the main goal of this study is to analyze the association between a set of genetic polymorphisms involved in apoptosis and tumor suppression and the risk of developing prostate cancer (PCa) in a population from Galicia. Accordingly, we performed a case-control study with 291 patients diagnosed with PCa and 249 healthy controls. A total of 19 genetic polymorphisms located in loci <i>BCL2</i>, <i>CASP9</i>,<i> CASP8</i>,<i> CASP7</i>,<i> FAS</i>,<i> FASLG</i>,<i> BIRC5</i>,<i> TP53</i>,<i> MDM2</i>, and <i>MDM4</i> were genotyped. Their association with PCa was approached from a global perspective and stratified by the body mass index (BMI). Globally, a statistically significant association with PCa was found for polymorphisms rs1052576 (<i>CASP9</i>) and rs990431 (BIRC5), with carriers of the G allele (OR<sub>GA/AA</sub> = 2.14; <i>p</i> = 0.002) or the CC genotype (OR<sub>CC/CG</sub> = 1.92; <i>p</i> = 0.037), respectively, manifesting greater susceptibility to the disease. The analyses stratified by BMI yielded statistically significant results for polymorphisms rs1052576 (<i>CASP9</i>), rs3740286 (<i>FAS</i>), rs9904341 (<i>BIRC5</i>), rs2279744 (<i>MDM2</i>), rs937283 (<i>MDM2</i>), and rs1380576 (<i>MDM4</i>), with odds ratios between 2.47 and 8.00 in overweight or obese participants. These results indicate the differential effect of allelic variants of six SNPs on prostate cancer risk in patients with overweight or obesity. Further studies in larger cohorts should be conducted to confirm these findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of apoptotic genetic polymorphisms in prostate cancer susceptibility in a North West Spain population

  • 期刊论文

  • 发表日期：

    2026年3月31日

查看全文
  • N. López-Trigo,
  • B. Caeiro,
  • J. Pérez-Pérez,
  • A. Rodríguez-Alonso,
  • N. Aguín,
  • J. A. Rodríguez,
  • J. R. Luis

摘要

Apoptosis and tumor suppression prevent cell proliferation in response to genomic damage. Polymorphisms in genes involved in these pathways can alter their function, facilitating the onset of cancer. Detecting these polymorphisms would assess the individual risk of developing different types of cancer. Therefore, the main goal of this study is to analyze the association between a set of genetic polymorphisms involved in apoptosis and tumor suppression and the risk of developing prostate cancer (PCa) in a population from Galicia. Accordingly, we performed a case-control study with 291 patients diagnosed with PCa and 249 healthy controls. A total of 19 genetic polymorphisms located in loci BCL2, CASP9, CASP8, CASP7, FAS, FASLG, BIRC5, TP53, MDM2, and MDM4 were genotyped. Their association with PCa was approached from a global perspective and stratified by the body mass index (BMI). Globally, a statistically significant association with PCa was found for polymorphisms rs1052576 (CASP9) and rs990431 (BIRC5), with carriers of the G allele (ORGA/AA = 2.14; p = 0.002) or the CC genotype (ORCC/CG = 1.92; p = 0.037), respectively, manifesting greater susceptibility to the disease. The analyses stratified by BMI yielded statistically significant results for polymorphisms rs1052576 (CASP9), rs3740286 (FAS), rs9904341 (BIRC5), rs2279744 (MDM2), rs937283 (MDM2), and rs1380576 (MDM4), with odds ratios between 2.47 and 8.00 in overweight or obese participants. These results indicate the differential effect of allelic variants of six SNPs on prostate cancer risk in patients with overweight or obesity. Further studies in larger cohorts should be conducted to confirm these findings.